Bai Ze Medical to Raise HK$6.24 Billion in Global Share Offering

Bai Ze Medical, a leading oncology-focused healthcare group, has announced its global offering of approximately 133 million shares from June 13 to June 18, 2025. The offering is structured to include about 10% of the shares for sale in China Hong Kong and 90% for international sale. The price range for each share is set between 4.22 and 6.75 Hong Kong dollars, with a minimum purchase of 600 shares per lot. The company anticipates that the shares will be listed on the stock exchange by June 23, 2025.

Bai Ze Medical operates and manages eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces, focusing on providing comprehensive oncology care. The group's portfolio includes six for-profit private hospitals and two non-profit private hospitals, highlighting its commitment to delivering specialized cancer treatments.

Harvest Oriental has been identified as a cornerstone investor in this offering. This strategic move is expected to bolster the company's financial position and enhance its market presence. The inclusion of Harvest Oriental as a cornerstone investor underscores the confidence in Bai Ze Medical's growth prospects and its potential to deliver strong returns to investors. Harvest Oriental has agreed to subscribe or purchase shares under certain conditions, with the total amount estimated to be around 19 million US dollars, excluding brokerage commissions, securities regulatory transaction fees, and stock exchange transaction fees. Assuming the offering price is 5.49 Hong Kong dollars per share, Harvest Oriental is expected to subscribe to approximately 27.15 million shares.

Assuming the offering price is 5.49 Hong Kong dollars per share, after deducting underwriting fees, commissions, and estimated expenses related to the global offering, Bai Ze Medical estimates that it will receive approximately 6.24 billion Hong Kong dollars in net proceeds from the global offering. The company plans to allocate these funds as follows: approximately 35.7% to enhance its comprehensive oncology care services, 30.6% to acquire hospitals in new markets that meet specific criteria, 15.3% to expand its hospital management business, 10.2% to upgrade its information technology infrastructure and systems, and 8.1% for working capital and other general corporate purposes.

This global offering represents a significant milestone for Bai Ze Medical as it seeks to expand its reach and capitalize on the growing demand for healthcare services. The company's decision to list its shares on the stock exchange demonstrates its commitment to transparency and accountability, providing investors with a clear pathway to participate in its success. The offering is expected to attract a diverse range of investors, both domestically and internationally, further solidifying Bai Ze Medical's position as a leader in the oncology healthcare sector.